Behcet Disease - Pipeline Review, H1 2018

  • ID: 4515981
  • Report
  • 66 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Celgene Corp
  • Coherus BioSciences Inc
  • Genor BioPharma Co Ltd
  • Novartis AG
  • R Pharm
  • MORE
Behcet Disease - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Behcet Disease - Pipeline Review, H1 2018, provides an overview of the Behcet Disease (Cardiovascular) pipeline landscape.

Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Behçet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals(sex organs). More serious symptoms can include inflammation (swelling, heat, redness, and pain) in the eyes and other parts of the body. The goal of treatment is to reduce pain and prevent serious problems.

Report Highlights:

This latest Pharmaceutical and Healthcare disease pipeline guide pipeline guide Behcet Disease - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Behcet Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Behcet Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Behcet Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 1, 1, 1, 3 and 1 respectively.

Behcet Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researechers' proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Behcet Disease (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Behcet Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Behcet Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Behcet Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Behcet Disease (Cardiovascular)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Behcet Disease (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Behcet Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Celgene Corp
  • Coherus BioSciences Inc
  • Genor BioPharma Co Ltd
  • Novartis AG
  • R Pharm
  • MORE
Introduction

Report Coverage

Behcet Disease - Overview

Behcet Disease - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Behcet Disease - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Behcet Disease - Companies Involved in Therapeutics Development

AbbVie Inc

Celgene Corp

Coherus BioSciences Inc

Genor BioPharma Co Ltd

Novartis AG

R Pharm

Behcet Disease - Drug Profiles

adalimumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

apremilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

canakinumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infliximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPH-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Behcet Disease - Dormant Projects

Behcet Disease - Discontinued Products

Behcet Disease - Product Development Milestones

Featured News & Press Releases

Feb 17, 2018 : OTEZLA (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behcet's Disease with Oral Ulcers

Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir

Mar 23, 2016: Turkish signature on the biomolecules study - Hurriyet

Apr 15, 2015: Phase II Data for Apremilast in Behçet's Disease Published in The New England Journal of Medicine

Jun 14, 2013: Celgene Presents Results From Phase II Trial Of Oral Apremilast In Patients With Behçet’s Disease At EULAR

May 24, 2013: AbbVie And Eisai Receive Indication Approval For Treatment Of Intestinal Behcet's Disease For Humira Pre-filled Syringe In Japan

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Behcet Disease, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Behcet Disease - Pipeline by AbbVie Inc, H1 2018

Behcet Disease - Pipeline by Celgene Corp, H1 2018

Behcet Disease - Pipeline by Coherus BioSciences Inc, H1 2018

Behcet Disease - Pipeline by Genor BioPharma Co Ltd, H1 2018

Behcet Disease - Pipeline by Novartis AG, H1 2018

Behcet Disease - Pipeline by R Pharm, H1 2018

Behcet Disease - Dormant Projects, H1 2018

Behcet Disease - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Behcet Disease, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Celgene Corp
  • Coherus BioSciences Inc
  • Genor BioPharma Co Ltd
  • Novartis AG
  • R Pharm
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll